Media and Communications

News

NA

Friday, November 07, 2014
Teva Presents Data for Investigational Short-Acting Beta-Agonist Inhaler (Albuterol MDPI) at 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

Late Stage Data from Multiple Studies Showcase Safety and Efficacy Profile JERUSALEM--(BUSINESS WIRE)--Nov. 7, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that four company-sponsored abstracts evaluating the safety and efficacy of albuterol multi-dose dry-powder inhaler (MDPI), an investigational breath-actuated, dry-powder, short-acting beta-agonist (SABA), will be presented at the 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Atlanta, Georgia Read More »

Friday, November 07, 2014
Teva Presents Positive Safety and Efficacy Data for QNASL® (Beclomethasone Dipropionate) Nasal Aerosol in Treating Children with Perennial Allergic Rhinitis

Late Stage Data to be Presented at ACAAI 2014 JERUSALEM--(BUSINESS WIRE)--Nov. 7, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced positive findings from a Phase III clinical study that examined the safety and efficacy of QNASL® (beclomethasone dipropionate) Nasal Aerosol 80 μg/day in children 4-11 years of age with perennial – or “year round” – allergic rhinitis (PAR). QNASL is a waterless aerosol intranasal corticosteroid spray currently available for the treatment of PAR and seasonal allergic rhiniti Read More »

Tuesday, November 04, 2014
Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington’s Disease Trial

ARPEGGIO and LEGATO-HD trials will further evaluate the effect of laquinimod in neurodegenerative diseases JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Nov. 4, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) today announced the expansion of the laquinimod clinical development program with the initiation of the ARPEGGIO trial, which will evaluate the potential of laquinimod to treat primary progressive multiple sclerosis (PPMS). Additionally, Teva has screened the first patie Read More »

Wednesday, October 08, 2014
Teva Announces Initiation of New Drug Application and Positive Results from Second Human Abuse Liability Study for CEP-33237 (Hydrocodone Bitartrate) Extended-Release Tablets

Comprehensive clinical development program, including nasal and oral HAL studies,support NDA submission for investigational pain medication formulated with Teva’s proprietary abuse deterrence technology JERUSALEM--(BUSINESS WIRE)--Oct. 8, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced the initiation of a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration for hydrocodone bitartrate extended-release tablets designed with Teva’s proprietary technology providing potentia Read More »

Monday, October 06, 2014
Teva Announces Results of Strategic Review of Core Specialty Therapeutic Areas

- Affirms its long-term commitment to being a world-leader in Central Nervous System and Respiratory - - Maintains its current commercial presence but stops Research & Development in other therapeutic areas, including Oncology and Women's Health - JERUSALEM--(BUSINESS WIRE)--Oct. 6, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced the results of its strategic review of core therapeutic areas for the Company. The review included an extensive evaluation of Teva’s current and futur Read More »

Monday, September 08, 2014
Successful Completion of Phase III Program for Teva’s Reslizumab Two More Phase Iii Studies Support the Benefits of Reslizumab Treatment in Asthma Patients with Eosinophilia

New Phase III data presented at European Respiratory Society Congress (ERS) builds on recent exacerbation reduction data, creating a special efficacy profile for reslizumab Reslizumab shown to significantly improve lung function and asthma control Findings support reslizumab benefits specifically for moderate to severe asthma patients with elevated level of blood eosinophils JERUSALEM--(BUSINESS WIRE)--Sep. 8, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced Read More »

Thursday, September 04, 2014
Teva Announces Launch of Generic Baraclude® Tablets, 0.5mg and 1mg, in the United States

JERUSALEM--(BUSINESS WIRE)--Sep. 4, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announces the launch of the generic equivalent to Baraclude® (Entecavir) Tablets, 0.5mg and 1mg, in the United States. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Baraclude® (Entecavir) Tablets, 0.5mg and 1mg, marketed by Bristol-Myers Squibb, had annual sales of approximately $328 million in the United States, according to IMS data as of June 2014. About Teva Te Read More »

Thursday, September 04, 2014
Teva to Present at the Morgan Stanley Global Healthcare Conference

JERUSALEM--(BUSINESS WIRE)--Sep. 4, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the Morgan Stanley Global Healthcare Conference. Eyal Desheh, EVP & CFO will present on Monday, September 8, 2014 at 9:55 AM ET   What: Teva Presentation at the Morgan Stanley Global Healthcare Conference Read More »

Wednesday, September 03, 2014
Teva Announces UK High Court Gives Positive Judgment in the Company’s Patent Case Against AstraZeneca

Court Decision Invalidating AZ's Patent Supports Teva’s Launch of DuoResp Spiromax® in UK JERUSALEM--(BUSINESS WIRE)--Sep. 3, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that a positive judgment has been given by the UK High Court in support of Teva's case against AstraZeneca relating to the validity of EP 1,085,877 covering the SMART (Single inhaler Maintenance And Reliever Therapy) indication for AstraZeneca's fixed dose formoterol/budesonide combination product, Symbicort®. The Cou Read More »

Wednesday, September 03, 2014
Data to be Presented at MS Boston 2014: Joint ACTRIMS-ECTRIMS Meeting Underscore Teva’s Commitment to Developing Solutions to Meet the Needs of the Multiple Sclerosis Community

JERUSALEM--(BUSINESS WIRE)--Sep. 3, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that more than 20 company-sponsored abstracts including data on COPAXONE® (glatiramer acetate injection) and laquinimod, an investigational therapy for multiple sclerosis (MS), will be featured at the MS Boston 2014: Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts, September 10 – 13, 2014. “Teva takes pride in its well-established presence in the MS community and on-going efforts to bring convenient, effective ther Read More »

​​​